sábado, 13 de octubre de 2018

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy | Biomarker Research | Full Text

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy | Biomarker Research | Full Text

Biomarker Research



New Content Item

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Biomarker Research20186:4
  • Received: 11 October 2017
  • Accepted: 2 January 2018
  • Published: 

Abstract

Severe cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T cell (CAR-T) therapy can be life-threatening in some cases, and management of those toxicities is still a great challenge for physicians. Researchers hope to understand the pathophysiology of CRS and neurotoxicity, and identify predictive biomarkers that can forecast those toxicities in advance. Some risk factors for severe CRS and/or neurotoxicity including patient and treatment characteristics have been identified in multiple clinical trials of CAR-T cell therapy. Moreover, several groups have identified some predictive biomarkers that are able to determine beforehand which patients may suffer severe CRS and/or neurotoxicity during CAR-T cell therapy, facilitating testing of early intervention strategies for those toxicities. However, further studies are needed to better understand the biology and related risk factors for CRS and/or neurotoxicity, and determine if those identified predictors can be extrapolated to other series. Herein, we review the pathophysiology of CRS and neurotoxicity, and summarize the progress of predictive biomarkers to improve CAR-T cell therapy in cancer.

Keywords

  • Chimeric antigen receptor
  • CAR-T
  • CRS
  • Neurotoxicity
  • Biomarker

No hay comentarios:

Publicar un comentario